The European Patent Office (EPO) has published patent application EP4630804A1, titled 'Ligands specific for ASCT1', on March 18, 2026. The publication details the applicants, including Metafora Biosystems and research institutions, as well as the inventors. The patent's International Patent Classification (IPC) includes G01N 33/00, A61K 38/16, C07K 14/005, and A61K 39/21, indicating its relevance to diagnostic methods and pharmaceutical compositions.

This patent publication does not impose direct compliance obligations on regulated entities. However, it is relevant for pharmaceutical and biotechnology companies involved in drug development, particularly those researching ASCT1 ligands. Legal and R&D departments should note this publication for potential intellectual property landscape analysis and freedom-to-operate assessments within the designated European states.